

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
03 November 2022 (03.11.2022)



(10) International Publication Number
WO 2022/229853 A1

(51) International Patent Classification:
C12N 7/00 (2006.01) C12N 15/864 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/IB2022/053880

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:
27 April 2022 (27.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/180,423 27 April 2021 (27.04.2021) US

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **BOSSE, Astrid**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **BOSSUGE, Benoit**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **CROUTE, Laurence**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **ELLENRIEDER, Lars**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **GUIANVARCH, Laurence**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). **SCHMITT, David**; 30 rue de Roggenberg, 68560 Hirsingue (FR). **TOFFOLI, Eleonora**; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH).

(74) Agent: **SCHWEIZER, Christiane**; K&L Gates LLP, Markgrafenstraße 42, 10117 Berlin (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: VIRAL VECTOR PRODUCTION SYSTEM

(57) Abstract: The disclosure provides, at least in part, to a method for producing high titer lentiviral vectors, and for producing lentiviral particles carrying a transgene of interest and under satisfactory safety conditions. The disclosure also provides at least in part, methods of purification of such lentiviral particle, e.g., from a cell culture. The disclosure also provides a formulation to lentiviral preparations that maintain structural integrity of the viral vector during purification, storage, and gene transfer events.

WO 2022/229853 A1